TABLE 3.
Viability assessment of ΔbamB ΔbamC ΔbamE, ΔbamD, and ΔbamC ΔbamD ΔbamE mutants in stationary-phase overnight cultures
| Genotype | CFU/ml ± SD (×108) (n = 3) |
|---|---|
| Tn7att::bamA | 11.5 ± 1.82 |
| Tn7att::bamAE470K | 11.7 ± 3.09 |
| Tn7att::bamAA496P | 12.4 ± 0.55 |
| Tn7att::bamAA499S | 13.9 ± 1.10 |
| ΔrcsF Tn7att::bamA | 11.0 ± 1.31 |
| ΔrcsF Tn7att::bamAE470K | 11.6 ± 2.32 |
| ΔrcsF Tn7att::bamAA496P | 12.7 ± 0.84 |
| ΔrcsF Tn7att::bamAA499S | 12.5 ± 3.98 |
| ΔbamB ΔbamC ΔbamE Tn7att::bamAE470K | 1.08 ± 0.19 |
| ΔbamB ΔbamC ΔbamE ΔrcsF Tn7att::bamAE470K | 0.32 ± 0.33 |
| ΔbamB ΔbamC ΔbamE ΔrcsF Tn7att::bamAA496P | 0.32 ± 0.18 |
| ΔbamB ΔbamC ΔbamE ΔrcsF Tn7att::bamAA499S | 0.463 ± 0.68 |
| bamD::kan Tn7att::bamAA496P | 0.241 ± 0.08 |
| bamD::kan ΔrcsF Tn7att::bamAA496P | 0.587 ± 0.23 |
| bamD::kan ΔrcsF Tn7att::bamAA499S | 0.611 ± 0.13 |
| ΔbamC ΔbamD ΔbamE Tn7att::bamAE470K | 1.16 ± 0.49 |
| ΔbamC ΔbamD ΔbamE ΔrcsF Tn7att::bamAE470K | 1.35 ± 0.33 |
| ΔbamC ΔbamD ΔbamE Tn7att::bamAA496P | 0.385 ± 0.06 |
| ΔbamC ΔbamD ΔbamE ΔrcsF Tn7att::bamAA496P | 0.7.32 ± 0.02 |
| ΔbamC ΔbamD ΔbamE ΔrcsF Tn7att::bamAA499S | 0.298 ± 0.06 |